Inhibrx Biosciences Q2 net loss widens on higher expenses

Inhibrx Biosciences

13/08/2026 21:12

Overview
US biopharmaceutical firm's Q2 2026 revenue was zero, down from prior-year period
Net loss for Q2 widened yr/yr as operating expenses increased
Company secured $100 mln in loan proceeds after quarter-end, increasing cash position

Result Drivers
R&D SPENDING - Co said higher research and development expenses were driven by increased clinical trial and contract manufacturing costs as it advanced clinical programs and prepared for regulatory filings
PRE-COMMERCIALIZATION COSTS - Co said higher general and administrative expenses were mainly due to additional pre-commercialization activities for ozekibart
HIGHER INTEREST EXPENSE - Co said increase in other expense, net was mainly due to higher interest expense on outstanding loan balance

Company press release: ID:nPn7mcnwVa

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Loss Per Share
Beat
$2.34
$2.39 (2 Analysts)
Q2 Net Loss
Miss
$36.65 mln
$29.62 mln (2 Analysts)

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
Wall Street's median 12-month price target for Inhibrx Biosciences Inc is $277.50, about 182.1% above its August 12 closing price of $98.36

Reuters Recommended Reads
Aug 11 - Oncology firm Immunome's Q2 net loss widens as R&D costs rise
Aug 11 - Erasca Q2 net loss widens on higher R&D costs
Aug 13 - Cellectar Biosciences Q2 net loss widens on higher R&D costs

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)